Skip to content

Author

Chloe T. Shi

We have 2 of 16 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

NCCN Risk Groups Do Not Predict Adverse Pathology or Oncologic Outcomes Among Patients With Grade Group 1 Prostate Cancer in the MRI Era.

BACKGROUND Prior studies in the pre-MRI era suggest that patients with NCCN Intermediate and High Risk Grade Group 1 prostate cancer (GG1 PCa) on biopsy have increased risk for adverse oncologic outcomes. However, prostate MRI has altered patient selection for biopsy and improved prostate sampling. Herein, we examined...

Eric V. Li, Tae-Hee Kim, Michael K. Wang et al. · 0 citations
Review 2026

Artificial intelligence in prostate cancer diagnosis and management: state-of-the-art approaches and emerging innovations.

This review summarizes the current state of AI applications in the diagnosis, risk stratification, and treatment of prostate cancer, highlighting recent advances and emerging opportunities in this ever-changing field.

Matthew S Lee, Chloe Shi, Tae-Hee Kim et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.